Lipedema—Pathogenesis, Diagnosis, and Treatment Options

Philipp Krupa, Iakovos Georgiou, Niklas Biermann, Lukas Prantl, Peter Klein-Weigel, and Mojtaba Ghods

Summary

Background: Lipedema is often unrecognized or misdiagnosed; despite an estimated prevalence of 10% in the overall female population, its cause is still unknown. There is increasing awareness of this condition, but its differential diagnosis can still be challenging. In this article, we summarize current hypotheses on its pathogenesis and the recommendations of current guidelines for its diagnosis and treatment.

Methods: This review is based on publications about lipedema that were retrieved by a selective search in the MEDLINE, Web of Science, and Cochrane Library databases.

Results: The pathophysiology of lipedema remains unclear. The putative causes that have been proposed include altered adipogenesis, microangiopathy, and disturbed lymphatic microcirculation. No specific biomarker has yet been found, and the diagnosis is currently made on clinical grounds alone. Ancillary tests are used only to rule out competing diagnoses. The state of the evidence on treatment is poor. Treatment generally consists of complex decongestive therapy. In observational studies, liposuction for the permanent reduction of adipose tissue has been found to relieve symptoms to a significant extent, with only rare complications. The statutory health-insurance carriers in Germany do not yet regularly cover the cost of the procedure; studies of high methodological quality will be needed before this is the case.

Conclusion: The diagnosis of lipedema remains a challenge because of the heterogeneous presentation of the condition and the current lack of objective measuring instruments to characterize it. This review provides a guide to its diagnosis and treatment in an interdisciplinary setting. Research in this area should focus on the elucidation of the pathophysiology of lipedema and the development of a specific biomarker for it.

Cite this as:

Lipedema is a chronic condition that is currently thought to be progressive as well. It mainly affects women, male sufferers having been described in only a few case reports (1) (e1, e2). Its progressive nature, though not yet unequivocally demonstrated, is assumed on the basis of clinical experience. Epidemiologic estimates from the sparse available data suggest an approximately 10% prevalence in the overall female population (2, 3, e3–e6).

The initial manifestations of lipedema often arise in phases of hormonal change (puberty, pregnancy, menopause). Its hallmark is a disproportionate distribution of body fat on the extremities, while the trunk remains slim. Hands and feet are not involved. (4) (Figure).

Aside from the circumscribed, bilaterally symmetrical, localized increase of the subcutaneous fatty tissue of the limbs, lipedema has the typical clinical manifestations listed in the Box (5). Three clinical stages have been described through which the disease progresses (Figure 1) (6).

Although Allan und Hines (7) described lipedema as early as 1940, the condition attracted little attention for many years. Even now that awareness of it has been heightened by frequent discussion in the news media (e7), there remains a great deal of uncertainty as to how it can be correctly diagnosed. The diagnosis is only rarely made on the patient’s first contact with a physician (e8), and there is often a delay of several years before specific treatment is initiated (8).

Current research focuses on the pathophysiology of lipedema and on the development of tools to facilitate its correct diagnosis and the exclusion of competing diagnoses. In this review, we present the current state of knowledge of, and hypotheses about, the etiology and pathogenesis of lipedema. We also hope to increase physicians’ awareness of the urgency of early diagnosis and promptly initiated treatment.

Method

We selectively searched for publications about lipedema in the MEDLINE (via PubMed), Web of Science, and Cochrane Library databases using the key words “Lipödem,” “lipedema,” “lipoedema,” and “multiple symmetric lipomatosis,” and we carried out a supplementary search among the references of these publications. We included articles that were published in English or German up to February 2020.

Department of Plastic, Aesthetic, Hand and Reconstructive Micro Surgery, Klinikum Ernst von Bergmann, Potsdam: Philipp Krupa, Iakovos Georgiou, Dr. med. Mojtaba Ghods
Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg: Dr. med. Niklas Biermann, Prof. Dr. Dr. med. Lukas Prantl
Department of Angiology, Klinikum Ernst von Bergmann, Potsdam: Dr. med. Peter Klein-Weigel

This article has been certified by the North Rhine Academy of Continuing Medical Education. The test questions for this article can be found at http://da.ebl.de/RY95. This unit can be processed for CME credit until 31 May 2021.

Participation is possible only via the Internet at cme.aerztebatt.de.
Pathophysiology

The cause of lipedema is still unexplained. There are various hypotheses about its pathophysiology (Figure 2).

As the condition has repeatedly been described in familial clusters, a genetic predisposition is assumed (9, e1, e9). As many as 60% of patients have an affected first-degree relative (3, 10, e9, e10). Analyses of familial clusters suggest an autosomal dominant inheritance pattern with incomplete penetrance (11, 12, e11).

As lipedema usually first manifests itself in periods of hormonal change, it is generally thought to be estrogen-mediated (13). Despite the autosomal dominant inheritance pattern suggested by pedigree analyses, it has been proposed that the disorder results from a polygenically mediated change in the pattern of distribution of alpha- and beta-estrogen receptors (ER) in the white fatty tissue of affected areas (ER-α expression ↓, ER-β expression ↑) (13, 14, e12).

It is not yet entirely clear whether, in lipedema, the subcutaneous fat cells become more numerous (hypertrophy) (15–17, e13, e14) or merely larger in size (hypertrophy) (15, e15).

Cytobiological and protein-expression studies on lipo-aspirates taken from lipedema patients suggest that the disorder mainly arises through changes in the initial steps of cell differentiation in adipogenesis (15, 16, 18–20).

Another pathophysiological hypothesis involves primary microvascular dysfunction in the lymphatic and blood capillaries (21, 22). This, in turn, is thought to be due to a hypoxic stimulus brought about by excessive expansion of adipose tissue, leading to endothelial dysfunction, and thereby to increased angiogenesis; alternatively, it may be due to a mechanical disturbance of lymph drainage (13, 17, 23, e16, e17). Capillary damage is also a proposed cause of the observed increased tendency to form hematomas and petechiae (21, 24).

Increased capillary permeability leads to shifting of protein into the extracellular compartment (“capillary leak”) and thereby to tissue edema. At first, the additional fluid entering the interstitial space can be compensated for by increased lymph drainage. As the disorder progresses, however, the capacity of the draining lymphatic vessels is exceeded, and high-volume insufficiency (e18) results, while the larger...
The advanced stages of lipedema are associated with various sequelae. A fluid load exceeding the capacity of the lymphatic system can cause secondary lymphedema (“lipo-lymphedema”) in any stage of the disease (12). Mechanical irritation from large fatty deposits near the joints can macerate the skin; such deposits on the thighs and around the knee joints can also interfere with normal gait and cause secondary arthritis (5). Further secondary effects include the emotional disturbance and lessened self-esteem that result from an appearance that falls short of the contemporary ideal of beauty (e7, e26).

**Diagnostic evaluation**
The diagnosis is generally made on clinical grounds after the exclusion of competing diagnoses. As the presenting manifestations of lipedema are heterogeneous, the diagnosis should be confirmed by an experienced lymphologist in doubtful cases. The basic diagnostic evaluation consists of history-taking, inspection, and palpation, with particular attention to the manifestations listed in the **Box**. The clinical constellation of the major manifestations of the disorder appearing together—tissue tenderness, a feeling of tightness, and an excessive tendency toward hematoma formation, with worsening symptoms over the course of the day, in a patient with a bilaterally symmetrical, disproportionate proliferation of fatty tissue on the limbs but not on the hands/feet—points toward the diagnosis of lipedema. Thus, the history obtained from the patient is a major factor in the establishment of the correct diagnosis.

Persons suffering from lipedema often have a positive family history of the disorder. The physician taking the history of the present illness must also ask, in particular, about the time of onset of the initial manifestations and progression in the intervening time.

The onset of lipedema is typically triggered by hormonal changes (puberty, pregnancy, menopause); this helps in the differentiation of lipedema from simple obesity. The distinction can be difficult to draw, as these entities often appear together and the clinical picture can vary (Table) (25). Even in an obese person, however, the characteristic symptoms of pain, a feeling of tightness, and a tendency toward bruising (hematoma formation) indicate that lipedema is present as well (Box). Sometimes lipedema is unmasked only after successful bariatric surgery for obesity, when, after marked weight loss, a persistent abnormal pattern of fat distribution reveals itself that is typical of lipedema (26, e27).

The physician taking the history must also routinely inquire about the commonly associated psychiatric comorbidities, so that early treatment of these can be initiated where necessary (e28).

**Clinical examination**
The three stages of the disease are characterized by progressive changes in the structure of the skin surface (stage I, smooth; stage II, uneven or corrugated; stage
Reduced mobility

Hypoxia

Microangiopathy of blood and lymphatic vessels

Hyperplasia/hyper trophy of adipocytes

Dysfunctional veno-arterial reflex

Macroangiopathy

Capillary fragility

Hyper-permeability

Hematoma/ petechiae

Lymphedema

Tissue fibrosis

Reduced mobility

Pain

Genetic factors

Hormonal factors

Other causes

Pro-inflammatory cytokines

Altered estrogen receptor pattern?

Hypoxia

Neurogenic inflammation

Reduction of elastic fibers

Increased volume of the limbs

Compression?

Magnet therapy

Note: the etiology of lipedema has not yet been conclusively determined.

The figure depicts a number of possible hypotheses about its pathogenesis.

### Hypotheses about pathogenesis

#### Laboratory tests

Renal and hepatic dysfunction, hypothyroidism (possibly subclinical), pathological lipid profiles, and insulin resistance should be ruled out by laboratory testing. Any hormonal or edema-promoting disturbances that are found should be treated, although no evidence yet indicates a benefit of such treatment with respect to the severity or course of lipedema (1).

#### Ancillary diagnostic testing

Diagnostic procedures that require special equipment are used only to rule out competing elements of the differential diagnosis; they play no established role in the routine evaluation of lipedema (3, 12, 27, e34, e35).

The skin and subcutaneous tissue can be studied qualitatively and quantitatively with ultrasonography (e36–e38), computed tomography (e39, e40), or magnetic resonance imaging (e41, e42).

Structural and functional evaluation of the lymphatic system with tests such as indirect lymphography (22, e43, e44), fluorescence micro-lymphography (21, e45), functional lymphatic scintigraphy (22, e9, e19, e21, e23, e46), and magnetic resonance lymphangiography (e47) does not reveal any specific or pathognomonic findings of lipedema.

3. markedly thickened and indurated) and in the findings on palpation:

- stage I: small nodules, reversible edema
- stage II: walnut-sized nodules, reversible or irreversible edema
- stage III: disfiguring fat deposits, macronodular changes, with accompanying lymphedema, potentially Stemmer sign positive (e29).

The symptoms and subjective degree of suffering are not necessarily correlated with the disease stage (5).

Standardized anthropometric measurements should be a part of routine clinical follow-up, both to assess the spontaneous course of the disorder and to monitor its response to treatment: body weight, body-mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio (WHR), and the circumference and volume of the limbs. The BMI is of limited utility in distinguishing lipedema from obesity (11, 25, e24).

Moreover, pain perception should be assessed at regular intervals, with, e.g., the Visual Analog Scale (VAS) and the Schmeller questionnaire (e30). An index of daily activity should also be documented, e.g., by the step-counting app of the patient’s mobile telephone (5).

The tissue tenderness that is characteristic of lipedema can be checked with the pinch test, which is often felt as very unpleasant in the affected areas but causes no pain elsewhere. Increased capillary fragility manifests itself in spontaneous hematoma formation. There is no need, in routine clinical practice, to document this further with any special measuring instruments or stress tests (e31–e33).
Other diagnostic methods, such as dual-energy X-ray absorptiometry (DEXA) (e48) or bioimpedance analysis (e49), are used only to answer certain specific questions that may arise.

**Treatment**

**Conservative management**

Ever since lipedema was first described, the consensus medical recommendation has been that patients should be advised to accept the condition and modify their mode of living accordingly. This remains true today, despite the availability of treatments that can bring relief (7). To prevent frustration, the physician must inform the patient that the main goal of conservative treatment is to relieve symptoms, not to improve the appearance of the extremities (17). No causally directed treatment for lipedema has yet been described.

The initiation, extent, and duration of treatment should be agreed on with the patient, in consideration of the individual degree of suffering caused by the disease. The classic components of conservative management are the following:

- manual lymph drainage, on a regular basis if necessary
- appropriate compression therapy with custom-made, flat-knitted compressive clothing (compression classes II–III)
- physiotherapy and exercise therapy
- psychosocial therapy
- dietary counseling and weight management
- patient education on self-management.

Although conservative management brings about only a small reduction in tissue volume—5–10% in various studies, including one randomized, controlled trial—it does lessen tenderness (pain on pressure) and feelings of tightness in the limbs (10, 24, 28, 29, e17, e50). A further goal of treatment is to prevent secondary complications, such as skin lesions in advanced disease (11).

Reports that several weeks of inpatient treatment can be beneficial (24, 28, 29, e17) do not imply any long-term benefit from outpatient treatment. In fact, there is hardly any evidence for the efficacy of conservative outpatient treatment “under the conditions of normal, everyday life,” and the authors therefore do not think conservative management can be considered the gold standard of treatment. Nor does any convincing evidence suggest that classic conservative management prevents the progression of the disease.

**Patient education**

Patients should be comprehensively informed about the nature of the disease and the fact that it is chronic. They should be told in a “non-ideological” way about all of the treatment options and about the ways they themselves can actively influence the disease. They should also be offered the option of professional help in coping emotionally with the disease. The pros and cons of confronting the patient with the diagnosis are discussed in detail by De la Torre et al. (25). As lipedema is a chronic, progressive condition, the patient should be given adequate informational material as soon as the diagnosis is made, along with contact data for the relevant self-help organizations. If necessary, the patient should also be educated about complex decongestive therapy (30).

**Weight control**

Patients with lipedema are at increased risk of developing morbid obesity (25); conversely, overweight worsens the manifestations of lipedema (11). The pathological subcutaneous fat in lipedema is considered to be diet-resistant (e51), but weight normalization can

<table>
<thead>
<tr>
<th>TABLE</th>
<th>The differential diagnosis of lipedema (modified from [5])</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lipedema</td>
</tr>
<tr>
<td>Sex</td>
<td>female</td>
</tr>
<tr>
<td>Family history</td>
<td>++</td>
</tr>
<tr>
<td>Symmetry</td>
<td>+++</td>
</tr>
<tr>
<td>Swollen feet</td>
<td>Ø</td>
</tr>
<tr>
<td>Increased fatty tissue</td>
<td>+++</td>
</tr>
<tr>
<td>Disproportion</td>
<td>+++</td>
</tr>
<tr>
<td>Edema</td>
<td>depending on stage Ø/+</td>
</tr>
<tr>
<td>Tenderness</td>
<td>+++</td>
</tr>
<tr>
<td>Hematoma tendency</td>
<td>+++</td>
</tr>
<tr>
<td>Influence of diet</td>
<td>(+)</td>
</tr>
</tbody>
</table>

* to +++ present, (+) possible, Ø absent
The primary care physician makes a provisional diagnosis of lipedema
- routine laboratory tests (creatinine, electrolytes, TSH, FBS, ASAT)
- personal and family history, comprehensive physical examination
- if lipedema is still suspected, refer to a specialized lymphologist, phlebologist, or angiologist who is experienced in the treatment of lipedema

The lymphologist/phlebologist/angiologist confirms the diagnosis
- further (ancillary) diagnostic testing for differential diagnoses:
  - obesity
  - lymphedema
  - chronic venous insufficiency
- comprehensive physical examination
  - objective description of morphology/Stemmer sign
  - body weight/height/BMI/waist-to-hip ratio/waist-to-height ratio
  - assessment of pain/general mobility/psychological manifestations

Stage I
- smooth skin surface
- evenly thickened, homogeneous subcutis with small nodules
- reversible edema (raising the limb)
- circadian rhythmicity

Stage II
- uneven, corrugated skin surface
- nodular structures in thickened subcutis
- reversible or irreversible edema
- moderate to severe fibrosis
- circadian rhythmicity

Stage III
- marked increase in size of extremities
- disfiguring fat deposits
- thickened, indurated subcutis with macronodular changes
- marked sclerosis and fibrosis
- often, concomitant lymphedema

Basic measures
- acceptance of the disease
- patient education
- lifestyle adaptation
- sport and exercise therapy
- opportunity to take part in self-help groups
- obesity treatment (interdisciplinary) as needed
- skin care
- weight management
- diet modification

Complex decongestive therapy
- regular manual lymph drainage (MLD)
- provision of custom-made, flat-knitted compression wear of class II–III
- in stage III: initial treatment with multilayered compression dressings before fitting of
  compression wear

Additive measures
- use of intermittent pneumatic compression devices as needed
- kinesiotaping as needed
- acceptance of the disease
- improved disease management
- reduction of psychosocial symptoms

Regular follow-up of the patient by the therapist, with the following goals:
- alleviation of pain
- increased mobility and activity
- weight control
- reduction of hematoma-forming tendency
- adequate skin care

At least 6 months of ineffective conservative treatment
- critical reevaluation of treatments and compliance to date by the lymphologist/phlebologist/angiologist
- recommendation of and referral for surgery by the treating lymphologist/phlebologist/angiologist
- preoperative psychological evaluation as indicated

Stages I–II
- reimbursement must generally be decided upon by the insurance carrier on an individual, case-by-case basis
- submission of an application for reimbursement

Stage III
- BMI <35 kg/m²: reimbursable
- BMI >35 kg/m²: accompanying guideline-based treatment of obesity is required
- BMI >40 kg/m²: the procedure should not be performed, the treatment of obesity has priority

Specialized center for lipedema surgery
(plastic surgery board certification or demonstration of qualification according to G-BA criteria)
- determination of indication for lymph-vessel-sparing liposuction with wet technique
- operation under tumescence local anesthesia (TLA) or general anesthesia
  - use of power-assisted, i.e., vibration-assisted systems (PAL) or water-jet-assisted systems (WAL)
  - if the amount of aspirated fat exceeds 3 L, postoperative observation for at least 12 hours

The patient presents with painful, disproportionate increase of limb size
## Key messages

- It is not yet clear whether lipedema should be best defined as a primary lipodystrophy (pathological adipogenesis) or as a primary microangiopathy of small blood and lymphatic vessels. No specific biomarker is yet available.
- Its estimated prevalence in the overall female population is 10%. The costs engendered by the treatment of lipedema are difficult to calculate, as it remains unclear what percentage of the affected persons need to be treated.
- The disease is diagnosed on clinical grounds, on the basis of its main manifestations: pain, a feeling of tension, and increased tendency to form hematomas in the affected areas. Ancillary diagnostic testing is recommended mainly to rule out competing diagnoses.
- Treatment is symptomatically oriented and based on complex decongestive therapy. Conservative treatment can lessen the painful feeling of tension and pressure, the tendency to form hematomas, and the sequelae of the disease.
- If conservative treatment is unsuccessful, lymph-sparing liposuction can be considered as a means of permanently reducing fatty tissue mass. Only low-level evidence supports this procedure to date; the long-term outcome of treatment is to be studied in a prospective interventional trial commissioned by the German Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA).

Nevertheless improve symptoms (e52). Obesity should be treated if necessary, as recommended in current guidelines.

### Dietary modification

There is no specific, evidence-based diet for patients with lipedema, as no randomized and controlled trials on this topic have been published. Current dietary approaches generally rely on empirical data and are designed to lower body weight through hypocaloric nutrition (e52), inhibition of systemic inflammation with anti-oxidative and anti-inflammatory components (e53–e55), and fluid removal (e54). Because many patients with lipedema also suffer from eating disorders (12, 25), dietary modification should be carried out under the care of a psychologist wherever possible (5).

### Complex decongestive therapy

Manual lymph drainage (MLD), compression therapy, exercise therapy, and skin care are the pillars of complex decongestive therapy (1, 24, 28, e17).

As for the use of intermittent pneumatic compression devices (IPC), 30 minutes of intermittent compression in addition to 30 minutes of MLD was not found to have any convincing, synergistic, beneficial effect on the symptoms of lipedema in a randomized trial carried out in the inpatient setting (28). When used in ambulatory care, however, intermittent compression may lessen the frequency of MLD and lessen both tissue tension and the patient’s symptoms. Only mild pressure should be applied in the supplementary use of IPC to treat lipedema, in order not to bring about the collapse of the superficial lymphatic vessels, with ensuing tissue damage (28).

Exercise therapy should be tailored to the patient’s individual needs and disease stage. In general, the beneficial types of sport are those typified by controlled, cyclical walking or running movements that activate the calf-muscle pump but do not cause any excessive tissue trauma (e32, e56). As the pressure gradient under water helps lessen edema, swimming, aqua-jogging, and aqua-gymnastics are recommended; exercise under water also puts less stress on the joints in overweight patients.

Patients who do not benefit from outpatient treatment can be hospitalized in specialized lymphological units for further care.

### Surgery

If the symptoms persist and impair the patient’s quality of life despite appropriate conservative management, the potential indication for liposuction should be evaluated (5). Its therapeutic benefit has not yet been evaluated in any randomized, controlled trials.

### Lymph-sparing liposuction

In five observational studies of liposuction for the lasting reduction of fatty tissue, with follow-up for up to eight years, significant relief of symptoms was found (31–35, e57, e58). Surgery brought about improvement both in subjective criteria (pain perception, feeling of tightness, tendency to form hematomas, quality of life) and in objectively measured variables, such as leg circumference and the frequency and extent of conservative treatment. Complication rates were low and corresponded to the reported rates after liposuction in larger cohorts of patients who did not have lipedema (1% hemorrhage, 4% erysipelas, 4.5 % wound infection).

The available evidence in favor of liposuction for lipedema still does not document its efficacy clearly enough to justify its inclusion in the German health insurers’ catalog of regularly reimbursable procedures; whether it can be reimbursed must be decided in each individual case (36). Its long-term therapeutic benefit is now being investigated in a prospective, randomized multicenter trial sponsored by the German Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA) (e59). For the time being, this treatment is only selectively reimbursed by the statutory health-insurance carriers after individual case assessment, and it is thus mainly available to patients who have adequate financial resources to pay for it themselves.

Liposuction is, however, reimbursable as of January 2020 and until 31 December 2024 for patients with stage III lipedema who meet certain further conditions. Six months of prior conservative treatment are a prerequisite, and reimbursement further depends, to a great extent, on the patient’s BMI (Figure 3) (e60). Yet the BMI is of only limited utility for deciding on the indication for surgery, particularly in stage III patients who may have advanced fibrotic tissue changes in the involved areas of subcutaneous fat (e61). The patient self-help organizations have complained that these patients are receiving inadequate care (e62).
Patients in any stage of the disease whose weight exceeds 120 kg or whose BMI exceeds 32 kg/m² should be treated for obesity in conformity with current guidelines before the potential indication for liposuction is considered (5, 37). Liposuction should be performed with wet technique to spare the lymphatic vessels (33, 38–40, e63–e65). Patients from whom more than 3 L of pure adipose tissue have been aspirated should remain under qualified postoperative care for at least 12 hours after the procedure. The surgical techniques described in the literature differ from one another in many ways, but it is generally recommended that liposuction should be performed in multiple sittings, rather than a single sitting (40).

Surgical debulking

In highly advanced stages of the disease, with accompanying lymphedema, the involved tissue is so fibrotic that liposuction cannot adequately reduce its volume. In such cases, open surgical debulking (dermato-fibro-lipectomy) may be indicated (e66).

Conflict of interest statement

Dr. Klein-Weigel has served as a paid medicolegal expert for the Berlin Social Court (Sozialgericht Berlin) in cases related to the topic of this article. The other authors state that they have no conflict of interest.

Manuscript submitted on 4 December 2019, revised version accepted on 26 March 2020.

Translated from the original German by Ethan Taub, M.D.

References


Corresponding author

Dr. med. Mojtaba Ghods
Klinik für Plastische, Ästhetische und Rekonstruktive Mikrochirurgie/Handchirurgie
Klinikum Ernst von Bergmann, Charlottenstr. 72, D-14467 Potsdam, Germany
mghods@klinikumevb.de

Supplementary material

For eReferences please refer to: www.aerzteblatt-international.de/ref2220
**Supplementary material to:**

**Lipedema—Pathogenesis, Diagnosis, and Treatment Options**

by Philipp Kruppa, Iakovos Georgiou, Niklas Biermann, Lukas Prantl, Peter Klein-Weigel, and Mojtaba Ghods


---

eReferences

e60. G-BA: Methodenbewertung: Liposuktion wird befristet Kassenleistung bei Lip{"o}dem im Stadium III. www.g-ba.de/presse/pressemitteilungen/811/ (last accessed on 5 May 2020).
Questions for the article in issue 22–23/2020:

**Lipedema – Pathogenesis, Diagnosis and Treatment Options**

CME credit for this unit can be obtained via cme.aerzteblatt.de until 31. 5. 2021.

Only one answer is possible per question. Please select the answer that is most appropriate.

**Question 1**
What is the estimated prevalence of lipedema in the female population?
- a) 3%
- b) 6%
- c) 10%
- d) 12%
- e) 15%

**Question 2**
Which of the following is a risk factor associated with the development of lipedema?
- a) a carbohydrate-rich diet
- b) smoking
- c) lack of exercise
- d) prolonged standing
- e) positive family history

**Question 3**
Which of the following is a typical manifestation of lipedema?
- a) a feeling of tension in the affected limb
- b) hypertension
- c) body-mass index >28
- d) ankle-to-arm index <0.75
- e) excessively warm skin

**Question 4**
Which of the following features is characteristic of lipedema?
- a) improvement of symptoms over the course of the day
- b) sparing of the hands and feet
- c) insensitivity to pressure
- d) knee arthritis
- e) mild redness of the skin

**Question 5**
Which of the following is a feature of stage I lipedema?
- a) positive Stemmer sign
- b) irreversible edema
- c) subcuticular induration
- d) a smooth skin surface
- e) concomitant lymphedema

**Question 6**
What disease should be ruled out by laboratory testing in the differential diagnosis of lipedema?
- a) PCO syndrome
- b) gout
- c) hypothyroidism
- d) lysosomal storage disease
- e) celiac disease

**Question 7**
Which of the following is a central element of conservative treatment?
- a) Kneipp baths
- b) manual lymph drainage
- c) hypercaloric diet
- d) restricted fluid intake
- e) vibration training

**Question 8**
Which of the following is a typical finding in stage III lymphedema?
- a) small subcuticular nodules
- b) moderate increase in size
- c) skin eruption on the calves
- d) moderate fibrosis
- e) disfiguring fat deposits/tissue overhangs

**Question 9**
What type of sport is especially recommended for persons with lipedema?
- a) aqua-gymnastics
- b) power sports
- c) badminton
- d) rock climbing
- e) beach volleyball

**Question 10**
What surgical procedure is used to treat severe lipedema?
- a) lymphovenous anastomosis
- b) Roux-en-Y gastric bypass
- c) liposuction
- d) femoropopliteal bypass
- e) debridement